Aims & objectives: IMPROVE is a 6-month, multi-national, prospective, observational study, assessing the safety and efficacy of biphasic insulin aspart 30/70 (BiAsp 30) in patients with type 2 diabetes.
Methods: We present the efficacy data from the Indian cohort of IMPROVE study. A total of 17 995 subjects entered the study and 16 942 subjects completed the study. BiAsp 30 was initiated and dose was adjusted at the physicians discretion, reflecting everyday practice. Efficacy analysis set (EAS) includes 16 322 subjects. Efficacy was assessed by change in mean HbA1c, proportion of subjects achieving HbA1c targets (≤6.5%, <7%, target set by treating physicians), change in FBG, change in PPBG and change in FBG variability following 26 weeks of treatment.
Results: In comparison to baseline, there were significant reductions in mean HbA1c (n=15 624, 9.33 to 7.33%, P<0.001), FBG (n=14 935, 191 to 120 mg/dl, P<0.001), FBG variability (n=59, 21 to 11 mg/dl, P<0.001) and 2-hour post breakfast PPBG (n=10 319, 277 to 171 mg/dl, P<0.001) at the end of 26 weeks treatment. Significant improvement was also seen in proportion of subjects achieving HbA1c ≤6.5% (19%), HbA1c<7% (40%) and HbA1c target set by treating physicians (32%).
Conclusions: In this real life practice study, BiAsp 30 effectively improved glycemic parameters. Initiation of BiAsp 30 treatment significantly reduced mean HbA1c, FBG, 2-hour PPBG and FBG variability. There were also significant improvements in proportions of subjects achieving HbA1c targets. In conclusion, BiAsp 30 is an effective option for treating type 2 diabetes in Indian subjects.
25 - 29 Apr 2009
European Society of Endocrinology